Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5634293 | 1.00 | PPARD (0.44) | PPARDPPARA | |
| SCHEMBL5633863 | 0.86 | PPARD (0.53) | PPARDPPARA | |
| SCHEMBL5633861 | 0.86 | PPARD (0.53) | PPARDPPARA | |
| SCHEMBL5656293 | 0.84 | PPARD (0.43) | PPARD | |
| SCHEMBL5656286 | 0.84 | PPARD (0.43) | PPARD | |
| SCHEMBL5633496 | 0.79 | PPARA (0.52) | PPARDPPARA | |
| SCHEMBL5633491 | 0.79 | PPARA (0.52) | PPARDPPARA | |
| SCHEMBL5633466 | 0.78 | PPARD (0.55) | PPARDPPARA | |
| SCHEMBL5633464 | 0.78 | PPARD (0.55) | PPARDPPARA | |
| SCHEMBL5633007 | 0.78 | PPARD (0.44) | PPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7220877-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2007-05-22 | — | — | US | claimed |
| EP-1438283-A1 | DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | NOVO NORDISK A/S (DK) | 2004-07-21 | — | — | EP | claimed |
| US-20030109579-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2003-06-12 | — | — | US | claimed |
| WO-2003033453-A1 | DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2003-04-24 | — | — | WO | claimed |
| US-7220877-B2 | Compounds, their preparation and use | NOVO NORDISK A/S (DK) | 2007-05-22 | — | — | US | disclosed |
| EP-1438283-A1 | DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | NOVO NORDISK A/S (DK) | 2004-07-21 | — | — | EP | disclosed |
| US-20030109579-A1 | Novel compounds, their preparation and use | HIGH POINT PHARMACEUTICALS, LLC | 2003-06-12 | — | — | US | disclosed |
| WO-2003033453-A1 | DICARBOXYLIC ACID DERIVATIVES, THEIR PREPARATION AND THERAPEUTICAL USE | NOVO NORDISK A/S (DK) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030109579-A1 | Novel compounds, their preparation and use | PPARG, PPARA, PPARD | PPARD 3/4885PPARA 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.